3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Fallopian Tube Neoplasms
1
Congenital Abnormalities
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiotherapy
54
Temozolomide
50
Filgrastim
25
Cyclophosphamide
25
Etoposide
24
Cisplatin
22
Carboplatin
22
Vincristine
19
Chemotherapy, Adjuvant
18
Peripheral Blood Stem Cell Transplantation
15
Thiotepa
13
Carmustine
12
Thalidomide
10
Methotrexate
9
Magnetic Resonance Spectroscopy
9
Irinotecan
9
Bevacizumab
9
Granulocyte Colony-Stimulating Factor
7
sargramostim
6
Topotecan
6
Lomustine
6
X-Rays
5
Tamoxifen
5
Specimen Handling
5
Phantoms, Imaging
5
O(6)-benzylguanine
5
Ifosfamide
5
Erlotinib Hydrochloride
5
Drug Therapy
5
Celecoxib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Central Nervous System Neoplasms
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts